PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ulcerative Colitis

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Adults with Ulcerative Colitis

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Adults with Ulcerative Colitis

July 27, 2022

Sandoz Reports the EMA Acceptance of Hyrimoz (biosimilar, adalimumab) Application

Sandoz Reports the EMA Acceptance of Hyrimoz (biosimilar, adalimumab) Application

June 17, 2022

Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerative Colitis at DDW 2022

Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerati...

May 25, 2022

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcera...

May 24, 2022

Protagonist Reports Results of PN-943 in P-II (IDEAL) Study for the Treatment of Ulcerative Colitis

Protagonist Reports Results of PN-943 in P-II (IDEAL) Study for the Treatment of Ulcerative Colitis

April 27, 2022

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

March 28, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us